Longeveron(R) Announces Third Quarter 2025 Financial Results and Provides Business Update
(NASDAQ:LGVN),(NASDAQ:LGVNR), On track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication and is fully enrolled. ELPIS II may serve as foundation for a Biologics License Application […]